Transforming growth factor (TGF)-b, a cytokine with pleiotropic functions, plays a pivotal role in cancer biology and represents one of the key pathogenic factors in glioblastoma. Ligand binding leads to the phosphorylation of SMAD family proteins that are involved in the regulation of gene transcription. Activation of the TGF-b/SMAD pathway correlates with poor prognosis in glioma patients. 1 Various anti -TGF-b strategies have been explored in rodent glioma models 2 -5 and clinical trials. 6, 7 TGF-b signaling is mediated via a heterodimeric receptor complex comprising type I and type II receptors. 8 Canonical TGF-b signaling involves ligand binding to TGF-b receptor II (TGF-bRII), which associates with the type I receptor activin receptor-like kinase-5 (ALK-5) resulting in the phosphorylation of SMAD2 and SMAD3. 9 Pharmacological ALK-5 inhibition is an effective treatment strategy in rodent glioma models. 4, 5, 10 The involvement of another type I receptor in TGF-b signaling, the activin receptor-like kinase 1 (ALK-1), leading to the phosphorylation of SMAD1/5/8, has been characterized in endothelial cells. 11 This alternative pathway may counteract the ALK-5/ pSMAD2 pathway and thereby balance TGF-b signaling.
A role for TGF-b in modulating vascular endothelial growth factor (VEGF) release has been proposed in several cell types. Both negative and positive regulation of VEGF by TGF-b has been described in endothelial cells. 12, 13 In glioma cells, the effect of TGF-b on the regulation of VEGF release also remains uncertain. For selected glioma cell lines, a time-dependent increase of VEGF release induced by exogenous TGF-b has been reported. 14 Silencing of TGF-b 1/2 or exposure to the ALK-5 inhibitor, SD-208, led to reduced VEGF levels in the supernatant of LN-308 and LNT-229 glioma cells, indicating a role for TGF-b 1/2 in the regulation of constitutive VEGF release in vitro. 15 However, pharmacological inhibition of ALK-5 by SB431542 inhibited the TGF-b -evoked VEGF release but had only minor effects on constitutive VEGF release in D270MG or D423MG cells. 16 These observations raise the possibility that VEGF is not only regulated via pSMAD2/3 signaling but also involves other pathways in glioma cells.
Materials and Methods

Cell Culture
Nine long-term malignant glioma cell lines (LTCs), 17 4 glioma-initiating cell lines (GICs), 18, 19 and hCMEC/D3 20 (Supplementary material) were incubated under normoxia or in a hypoxia incubator (1% O 2 , 5% CO 2 , 378C).
Reagents
Recombinant TGF-b 2 (R&D Systems) was used for all stimulation studies. SD-208 (Scios Inc.) inhibits ALK-5 at 0.048 mM in cell-free systems. 4 
Immunoblot Analyses
Whole cell lysates were subjected to SDS-PAGE under reducing conditions loading equal amounts of proteins (Supplementary material). Short interference RNA (siRNA)-mediated knockdown was applied to identify the specific band. For quantitative correlation analyses of baseline expression of total and phosphorylated SMAD proteins, band intensity was analyzed via densitometry using ImageJ software (open source). To compare the relative induction of phosphorylation after stimulation, we scored the responses into no (,20%), low (20%-50%), medium (.50%) or high induction of phosphorylation (.100% or no baseline phosphorylation).
Real-time Polymerase Chain Reaction
Gene expression was determined via real-time polymerase chain reaction (RT-PCR; see Supplementary material for procedure and primer sequences) using glycerinaldehyde-3-phosphate dehydrogenase (GAPDH) as a housekeeping gene with the DC TT -method for relative quantification.
RNA Interference
To silence gene expression, cells were transiently transfected using Metafectene Pro (Biontex) for LTCs and electroporation for GICs (Neon Transfection System, Invitrogen) and siRNA pools (80 -120 nM final concentration), containing 4 selected siRNA duplexes, each with a modification pattern addressing off-target effects caused by both strands (ON-TARGETplus, SMARTpool, ON-TARGETplus Non-targeting siRNA Pool as a negative control; Dharmacon).
Flow Cytometry
Signal intensity of flow cytometry analysis (Supplementary material) was calculated as the ratio of mean fluorescence of specific versus isotype control antibody (specific fluorescence index).
Enzyme-linked Immunosorbent Assay
Supernatants (preparation as outlined in the Supplementary material) were analyzed by ELISA for VEGF levels (eBioscience) and TGF-b 1/2 (R&D Systems).
Luciferase Reporter Assay
The pGL3 SBE-4-Luc plasmid (B. Vogelstein) containing 4 copies of the SMAD-binding element (SBE) GTCTAGAC 21 was used for reporter gene assays (Supplementary material).
Results
TGF-b Pathway Activity in Human Glioma Cells
We first analyzed the expression levels of TGF-b receptors, their ligands, constitutive levels of total SMAD2-5, phosphorylated SMAD2, SMAD3 and SMAD1/5/8, and the TGF-b target gene plasminogen activator inhibitor (PAI)-1. Correlation analyses of these parameters were performed either for all cell lines pooled or separately for LTCs (Table 1) . A separate analysis for the GICs was omitted because of small sample size. We validated our results using Affymetrix gene expression data from the The Cancer Genome Atlas (TCGA) (Supplementary material, Table S1 ).
TGF-bRII, ALK-5, and ALK-1 messenger RNA (mRNA) were differentially expressed with a trend towards lower mRNA expression for all receptors in GICs. ALK-1 mRNA levels were lower than ALK-5 levels and more than 100 times lower in glioma than in endothelial cells (Fig. 1A -C, left) . The highest TGF-bRII protein levels were found for T98G cells, while 2 of 4 GICs (T-269, S-24) had TGF-bRII levels at the detection limit. The specific fluorescence index varied strongly for ALK-5 from 84 in LN-18 cells to 1.7 in LN-308 cells. ALK-1 protein was not detected at the cell surface in glioma cells using hCMEC as a positive control (Fig. 1A -C, right) . Overall, mRNA levels were not predictive of protein levels. TGF-b 1 and TGF-b 2 were heterogeneously expressed on mRNA and protein level ( Fig. 1D and E Table S1 ).
pSMAD2 levels were highest in LN-428, LN-319, A172 and LN-308, less in LN-18, D247 and T98G cells, below detection limit in the other cell lines, and correlated with pSMAD3 levels. pSMAD1/5/8 was low in 2 of 4 GICs (Fig. 1F) . TGF-bRII and ALK-5 mRNA correlated with pSMAD2, and TGF-bRII surface expression with pSMAD1/5/8 levels. Phosphorylation of SMAD proteins as the proximate readout of TGF-b activity correlated with ligand expression as follows: pSMAD2 with TGF-b 1 and TGF-b 2 mRNA; pSMAD3 and pSMAD1/5/8 with TGF-b 2 protein and inversely SMAD5 protein with the sum of TGF-b 1 and TGF-b 2 protein. PAI-1 mRNA levels did not correlate with TGF-b receptors, ligands (mRNA or protein), or downstream phosphorylation of SMAD (Fig. 1G, Table 1 ).
Endogenous TGF-b Promotes VEGF Expression and Release in a Cell Line-specific Manner VEGF expression on mRNA or protein level was similar in LTCs and GICs ( Fig. 2A and B) . TGF-b 1 mRNA correlated with VEGF Seystahl et al.: TGF-b-induced VEGF release in glioblastoma 1+2 protein n/a n/a n/a n/a n/a r ¼ 20. Abbreviation: mRNA, messenger RNA. Table S1 ). We chose LN-308 cells to study the regulation of constitutive VEGF release because of their high endogenous TGF-b expression and high constitutive SMAD2 and SMAD3 phosphorylation. We added selected analyses for U87MG and ZH-161 cells. In LN-308, TGF-bRII silencing with an efficacy of 88% reduction assessed by RT-PCR (data not shown) reduced pSMAD2 and pSMAD3 levels and confirmed the involvement of TGF-b and TGF-bRII in their constitutive regulation. Interestingly, pSMAD1/5/8 levels were also reduced upon silencing of TGF-bRII. Pharmacological inhibition of the kinase activity of ALK-5 by the small molecule inhibitor SD-208 or silencing of ALK-5 also led to reduced pSMAD2 and pSMAD3 levels but did not affect constitutive pSMAD1/5/8 levels (Fig. 2C) . To investigate the contribution of the different SMAD signaling pathways to constitutive VEGF release, we established gene silencing of SMAD2, SMAD3, SMAD2/3 in combination, or SMAD5, which led to specific reductions of the corresponding target proteins. As expected, pSMAD2, pSMAD3, and pSMAD1/5/8 were also reduced upon silencing of the respective SMAD proteins. In addition, silencing of SMAD proteins did not affect only their own phosphorylation; instead, we observed reduced pSMAD3 upon silencing of SMAD2 in contrast with increased pSMAD2 upon silencing of SMAD3. pSMAD3 was increased upon silencing of SMAD5, while pSMAD2 was unaffected (Fig. 2D) .
Silencing of TGF-bRII reduced VEGF release in LN-308 cells (Fig. 2E) . Inhibition of ALK-5 by RNA interference or SD-208 also reduced VEGF release in U87MG and LN-308 cells, although the reduction was not significant in ZH-161 (Fig. 2F) . SMAD silencing had differential effects on VEGF release: SMAD2 or SMAD3 gene silencing reduced constitutive VEGF levels in U87MG and LN-308 but not in ZH-161 (Fig. 2G) . Even cosilencing of SMAD2 and SMAD3 failed to affect VEGF release in ZH-161, but further reduced VEGF levels in LN-308 compared to the effect of silencing SMAD2 or SMAD3 alone. In contrast, silencing of SMAD5 increased the levels of constitutive VEGF release in U87MG cells but had no effects in LN-308 or ZH-161 (Fig. 2H) .
Exogenous TGF-b Promotes VEGF Release in Human Malignant Glioma Cells
We next assessed glioma cell response to exogenous TGF-b. All cell lines showed increased pSMAD2 and (except for S-24) increased pSMAD3, albeit to a different extent. The relative induction of pSMAD2 correlated inversely with the endogenous pSMAD2 (r ¼ 20.66; P ¼ .01). pSMAD1/5/8 was increased in LN-319, A172, and U87MG LTCs as well as T-325, ZH-161, and S-24 GICs (Fig. 3A) . We next monitored the increase of TGF-b -dependent transcriptional activity using a SBE reporter plasmid. 21 TGF-b induced SBE reporter activity in all cell lines except in LN-428, A172, T-269, and S-24 cells. The highest response was observed in U87MG (26-fold) (Fig. 3B) . Sufficient TGF-bRII surface expression was necessary for the induction of SBE reporter activity given the poor response in T-269 and S-24 cells, which exhibited TGF-bRII levels at the detection limit (Fig. 1A) . In addition, high responsiveness correlated with pSMAD3 induction by TGF-b (r ¼ 0.62; P ¼ .02). Surprisingly, the reporter-nonresponsive cell lines LN-428 and A172 expressed high levels of ALK-5, in contrast with the highly responsive cell line U87MG (Fig. 1B) .
VEGF levels increased after TGF-b treatment in all cell lines except LN-428, A172, and S-24. The most pronounced increase was seen in U87MG cells (9-fold) (Fig. 3C) . The response in U87MG was maintained but reduced in extent when those cells were switched to GIC culture conditions. In ZH-161, the response was further increased when switched to serumcontaining medium for 2 passages. Under GIC conditions, basal VEGF synthesis was increased in U87MG, both on mRNA and protein levels, and in ZH-161 on protein level (Supplementary material, Fig. S1 ). Cell lines not exhibiting TGF-b 2 -dependent VEGF induction showed only minor induction of pSMAD2 and pSMAD3 by TGF-b 2 (Fig. 3A) . The induction of VEGF by TGF-b correlated with the induction of pSMAD3 (r ¼ 0.59; P ¼ .04) and reporter responsiveness (r ¼ 0.71; P ¼ .006). To assess whether cell lines not increasing VEGF release in response to TGF-b were generally less responsive to transcriptional activation of the VEGF gene, we exposed the same cell lines to hypoxia (1% O 2 , 24 h) as a major driver of VEGF gene transcription. 22 Hypoxia led to increased VEGF levels in almost all cell lines including LN-428, A-172, and S-24, which did not increase VEGF release upon stimulation with TGF-b. Conversely, LNT-229 cells were unaffected, and D247MG even showed reduced VEGF release under hypoxia (Fig. 3D) . Of note, hypoxia-induced VEGF release was higher overall in GICs, ranging from 1.9-fold (ZH-161) to 32-fold (T-269) than in LTCs, ranging from 1.3-fold (LN-18) to 2.1-fold (U87MG). Accordingly, we found only minor induction of HIF-1a protein by hypoxia in LNT-229, which increased VEGF release in response to TGF-b but not to hypoxia. Indeed, we detected higher HIF-1a protein levels in ZH-161 than in LNT-229 cells under normoxic conditions. Of note, treatment with TGF-b left HIF-1a protein unaffected, and there was no correlation between the magnitude of the VEGF response to TGF-b versus hypoxia (data not shown). We selected U87MG and ZH-161 cells to examine the time and concentration dependence of VEGF induction by TGF-b. On mRNA level, the highest increase of VEGF (14-fold for U87MG and 1.4-fold for ZH-161) was observed at 4 hours for U87MG and at 24 -48 hours for ZH-161 (Fig. 3E) . The induction of VEGF release into the supernatant was highest at 9-fold at 24 hours in U87MG cells and 2-fold at 24 -48 hours in ZH-161 cells (Fig. 3F) . Furthermore, the induction of VEGF was concentration dependent in U87MG and ZH-161 cells both on mRNA (Fig. 3G ) and protein level (Fig. 3H ).
Molecular Pathways Mediating TGF-b -evoked VEGF Release in Glioma Cells
To explore the pathways mediating the stimulatory effect of exogenous TGF-b on VEGF release, we combined the inhibition of ALK-5 by SD-208 or siRNA, or siRNA-mediated gene silencing of SMAD2, SMAD3 or SMAD5, with the addition of exogenous Seystahl et al.: TGF-b-induced VEGF release in glioblastoma (Fig. 4A, right panel) . Silencing of SMAD2, SMAD3 or SMAD5 in U87MG or ZH-161 cells led to specific reductions of the target protein and reduced pSMAD2, pSMAD3, and pSMAD1/5/8 levels, respectively (Fig. 4B) . Interestingly, TGF-b 2 -induced SMAD1/5/8 phosphorylation was further increased in the case of SMAD2 or SMAD3 gene silencing in U87MG but not in ZH-161, consistent with substrate competition of SMAD proteins for ALK-5 (Fig. 4B) . TGF-b 2 -evoked transcriptional activity was reduced upon silencing of either SMAD2, SMAD3, or SMAD5 in U87MG. A similar trend was observed in ZH-161; however, the reduction was only significant upon silencing of SMAD3 alone or combined with SMAD2 (Fig. 4C) . In both cell lines, the TGF-b -evoked VEGF release was reduced upon silencing of SMAD2 or SMAD3. Cosilencing of SMAD2 and SMAD3 had no superior effect over single silencing in ZH-161. Further, silencing of SMAD5 reduced TGF-b 2 -evoked VEGF release in U87MG, but the reduction was not significant in ZH-161 cells (Fig. 4D) .
Discussion
Targeting angiogenesis is one of the major current strategies for glioblastoma treatment, but enthusiasm for this approach has declined after the failure of several antiangiogenic agents in phase III trials. 23 -25 Although the anti-VEGF antibody bevacizumab showed activity for recurrent glioblastoma in phase II trials, 26, 27 no survival gain was achieved in 2 phase III trials in newly diagnosed glioblastoma patients. 28, 29 Further, various attempts to improve antiangiogenic therapy by combination with cytotoxics were unsuccessful. 30 Nevertheless, VEGF is still one of the most promising targets that interferes with the malignant phenotype of glioblastoma. While hypoxia is considered the key driver of VEGF release in glioblastoma, hypoxia-independent control of VEGF release has received little attention.
TGF-b, an important molecule shaping the microenvironment in glioblastoma, was characterized here as a positive regulator of the VEGF pathway. We have provided a comprehensive analysis of the TGF-b pathway and its control of VEGF release in LTC and GIC models. Specifically, we analyzed the role of endogenous TGF-b as a model of autocrine signaling versus that of exogenous TGF-b, mimicking paracrine signals from the microenvironment. As a precondition for autocrine signaling, TGF-bRII and ALK-5 were widely expressed, whereas ALK-1 was not (Fig. 1) , which indicates that an ALK-1/ pSMAD1/5/8 signaling axis of VEGF release characterized in endothelial cells 12 does not operate in glioma cells. All LTCs released TGF-b 1 and TGF-b 2 , but TGF-b 2 was not detected in 2 of 4 GICs, confirming that therapeutic approaches targeting only one TGF-b isoform are insufficient. Most cell lines exhibited phosphorylated SMAD2, SMAD3, or SMAD5, suggesting constitutive TGF-b pathway activation, confirmed by reduced pSMAD levels when TGF-bRII or ALK-5 expression were suppressed, or when ALK-5 was inhibited pharmacologically (Fig. 2C) . In nonendothelial cells, bone morphogenetic proteins (BMP) are considered as major drivers of SMAD1/5/8 phosphorylation; however, TGF-b -dependent phosphorylation of SMAD1/5/8 has been recently described (although not yet for glioma cells). 31, 32 We found that pSMAD1/5/8 levels in cellular lysates correlated with TGF-bRII levels at the surface and that TGF-bRII gene silencing reduced pSMAD1/5/8 levels (Fig. 2C) . That inhibition of ALK-5 via SD-208 or ALK-5 gene silencing left pSMAD1/5/8 unaffected suggests that a type-I receptor other than ALK-5 mediates SMAD1/5/8 phosphorylation in response to TGF-b. Still, we cannot rule out that these effects are mediated via minor ALK-1 levels escaping detection on protein level.
To study the effect of endogenous TGF-b signaling on constitutive VEGF release, we experimented with different components of the TGF-b pathway. TGF-bRII gene silencing reduced VEGF release in LN-308 cells, which confirmed a role for TGF-b in the regulation of VEGF release in this cell line that releases high levels of active TGF-b 33, 34 (Fig. 2E) . Furthermore, VEGF release required ALK-5 activity in LN-308 and U87MG cells but not in ZH-161 cells (Fig. 2F) . This might suggest a robust TGF-b-independent VEGF secretion in GICs, which was potentially due to constitutive HIF expression at normoxic conditions 35 and was confirmed for ZH-161. SMAD2 and SMAD3 are necessary for TGF-b -dependent regulation of VEGF in LN-308 and U87MG cells, but again ZH-161 was unaffected, even by the combined SMAD2/3 silencing that reduced VEGF most efficiently in LN-308 cells (Fig. 2G) . The role of SMAD5 in the regulation of constitutive VEGF release is more complex. LN-308 and ZH-161 did not show major changes upon SMAD5 gene silencing, whereas U87MG showed increased VEGF secretion (Fig. 2H ). This can be explained by an indirect effect of BMP-2 being expressed by U87MG 36 and destabilizing HIF-1a in glioma cells. 37 Thus, depletion of SMAD5, resulting in reduced BMP signaling, might increase the stability of HIF-1a and thereby promote VEGF release. Furthermore, a direct inhibitory effect of BMP-9 on VEGF via ALK-1/pSMAD1/5/8 signaling has been described in endothelial cells. 38 Thus, TGF-b contributes to constitutive VEGF release in glioma cells via a TGF-bRII/ALK-5/SMAD2/3 signaling pathway. The pSMAD1/5/8 signaling axis, which is driven by both TGF-b and BMP, might be indirectly involved in selected cell lines, possibly as a negative feedback mechanism.
TGF-b is secreted not only by glioma cells but also by the tumor microenvironment (eg, endothelial, immune, or microglial cells). Thus, we studied the effect of exogenous TGF-b on VEGF release. We observed a differential pattern of responsiveness to TGF-b as determined by changes in SMAD phosphorylation and reporter activity (Fig. 3A and B) . We found that SMAD1/ 5/8 is also phosphorylated via TGF-b and ALK-5 in some glioma cell lines and may contribute to enhanced VEGF release (Fig. 3A,  Fig. 4A and D) . Sufficient TGF-bRII cell surface expression and phosphorylation of SMAD2/3 are necessary, but not sufficient, for SBE activation (Fig. 3B ) and VEGF release (Fig. 3C) high constitutive levels of pSMAD2 negatively correlated with the inducibility of pSMAD2 by exogenous TGF-b suggests a saturation of the signaling pathway by autocrine TGF-b that leads to decreased sensitivity towards exogenous TGF-b. ALK-5 expression was not predictive for sensitivity to exogenous TGF-b because cell lines with poor activation of the SBE reporter expressed rather high levels of ALK-5 and vice versa. Posttranscriptional processes (eg, involving deubiquitinating enzymes regulating TGF-b receptor stability 39 ) probably modulate sensitivity towards TGF-b.
Exogenous TGF-b induced VEGF release in most cell lines (Fig. 3C) . Cells unresponsive to TGF-b were still responsive to hypoxia with regard to VEGF induction, placing differential regulation upstream of the VEGF promoter (Fig. 3D) . TGF-b-dependent SMAD3 phosphorylation and transcriptional SBE activation correlated with TGF-b-evoked VEGF release, although no such correlation was seen for pSMAD2 or the TGF-b target gene, PAI-1. A differential activation of the transcription factor Sp1, a major driver of VEGF gene expression in nonhypoxic conditions 40 via competing SMAD signaling pathways, might play a role in this context. Of note, the VEGF promoter itself contains SBE sites, and promoter activity is increased by SMADs. 41 That depletion of SMAD5 led to increased constitutive VEGF release (Fig. 2H ), but reduced TGF-b evoked VEGF release (Fig. 4D ) in U87MG cells might be best explained via the dual activation of pSMAD1/5/8 by TGF-b and BMP. While endogenous BMP signaling might inhibit constitutive VEGF expression, either indirectly via destabilization of HIF 37 or directly via BMP-9-ALK1 signaling as described for endothelial cells, 38 a relative predominance of TGF-b signaling might occur in the pharmacological context of exogenous stimulation by TGF-b inducing VEGF both via pSMAD2/3 and pSMAD1/5/8 signaling (Fig. 5) .
In summary, we show that TGF-b regulation of VEGF release in glioma cells depends, in an ALK-5 -dependent manner, not only on SMAD2/3-dependent pathways but also on pSMAD1/ 5/8 signaling, suggesting that anti-TGF-b strategies may indirectly inhibit VEGF pathway activation in glioblastoma and that this mechanism accounts for some of the angiogenic activity attributed to TGF-b. Moreover, since we have recently illustrated how integrin inhibition downregulates TGF-b pathway activation in glioblastoma, 42 combinatorial therapeutic approaches targeting sequentially or parallel integrins TGF-b and VEGF based on preferential pathway activation may allow better treatment options for glioblastoma.
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